| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 127 securities · passive | ||||||
|
Praxis Precision Medicines, Inc
13G/A
PRAX · 74006W207
|
12.3% |
11/14/2025
Event 9/30/2025
|
||||
| Janus Henderson Group PLC | 12.3% | |||||
| Janus Henderson Biotech Innovation Master Fund Ltd | 6.2% | |||||
|
Consensus Cloud Solutions, Inc.
13G/A
CCSI · 20848V105
|
13.1% |
11/14/2025
Event 9/30/2025
|
||||
| Janus Henderson Group PLC | 13.1% | |||||
| Janus Henderson Triton Fund | 7.0% | |||||
|
Api Group Corp
13G
APG · 00187Y100
|
5.3% |
11/14/2025
Event 9/30/2025
|
||||
|
Verona Pharma PLC
13G/A
VRNA · 925050106
|
1.2% |
11/14/2025
Event 9/30/2025
|
||||
|
Amdocs Limited
13G/A
DOX · G02602103
|
2.3% |
11/14/2025
Event 9/30/2025
|
||||
|
Enanta Pharmaceuticals, Inc.
13G
ENTA · 29251M106
|
12.1% |
11/7/2025
Event 10/31/2025
|
||||
| Janus Henderson Group PLC | 12.1% | |||||
| Janus Henderson Biotech Innovation Master Fund Ltd | 10.6% | |||||
|
89bio, Inc.
13G/A
ETNB · 282559103
|
3.6% |
10/7/2025
Event 9/30/2025
|
||||
|
Aramark
13G/A
ARMK · 03852U106
|
6.9% |
8/14/2025
Event 6/30/2025
|
||||
|
Larimar Therapeutics, Inc.
13G/A
LRMR · 517125100
|
0% |
8/14/2025
Event 3/31/2025
|
||||
|
OmniAb, Inc.
13G/A
OABI · 68218J103
|
0.8% |
8/14/2025
Event 6/30/2025
|
||||
|
Entrada Therapeutics, Inc.
13G/A
TRDA · 29384C108
|
4.0% |
8/14/2025
Event 6/30/2025
|
||||
|
The Beauty Health Company
13G/A
SKIN · 88331L108
|
4.5% |
8/14/2025
Event 6/30/2025
|
||||
|
Walker & Dunlop, Inc
13G/A
WD · 93148P102
|
4.6% |
8/14/2025
Event 6/30/2025
|
||||
|
Globus Medical, Inc.
13G/A
GMED · 379577208
|
6.1% |
5/14/2025
Event 3/31/2025
|
||||
|
Mereo Biopharma Group PLC
13G/A
MREO · 589492107
|
14.3% |
5/14/2025
Event 3/31/2025
|
||||
| Janus Henderson Group PLC | 14.3% | |||||
| Janus Henderson Biotech Innovation Master Fund Ltd | 12.7% | |||||
|
CARGO Therapeutics, Inc.
13G/A
CRGX · 14179K101
|
0% |
5/14/2025
Event 3/31/2025
|
||||
|
Immunome, Inc.
13G/A
IMNM · 45257U108
|
2.2% |
5/14/2025
Event 3/31/2025
|
||||
|
Zai Lab Ltd
13G/A
G9887T116
|
3.6% |
5/14/2025
Event 3/31/2025
|
||||
|
Blackbaud, Inc.
13G/A
BLKB · 09227Q100
|
4.3% |
5/14/2025
Event 3/31/2025
|
||||
|
Perspective Therapeutics, Inc.
13G/A
CATX · 46489V302
|
0% |
2/14/2025
Event 12/31/2024
|
||||
|
Applied Therapeutics, Inc.
13G/A
APLT · 03828A101
|
0% |
2/14/2025
Event 12/31/2024
|
||||
|
PepGen Inc.
13G/A
PEPG · 713317105
|
1.6% |
2/14/2025
Event 12/31/2024
|
||||
|
Caesars Entertainment, Inc.
13G/A
CZR · 12769G100
|
3.3% |
2/14/2025
Event 12/31/2024
|
||||
|
Precision BioSciences, Inc.
13G/A
DTIL · 74019P207
|
0% |
2/14/2025
Event 12/31/2024
|
||||
|
NeoGenomics, Inc.
13G/A
NEO · 64049M209
|
4.8% |
2/14/2025
Event 12/31/2024
|
||||
|
Neurogene Inc.
13G/A
NGNE · 64135M105
|
0% |
2/14/2025
Event 12/31/2024
|
||||
|
CytomX Therapeutics, Inc.
13G/A
CTMX · 23284F105
|
0% |
2/14/2025
Event 12/31/2024
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.